Shares of Onesource Specialty Pharma Ltd. surged as much as 14% on Tuesday, October 27, hitting a three-week high of ₹1,589 as investors cheered the company's September quarter performance. According to reports from Livemint, the stock was trading 14% higher following the release of strong Q2 results, demonstrating positive market response to the company's operational performance. The pharmaceutical company announced its Q2 results during market hours, with the stock recovering 50% from recent lows and putting it on track for its biggest monthly gain in recent months.
The company reported revenue of ₹516.2 crore, representing a 37% year-on-year growth and 15% quarter-on-quarter growth, marking its third consecutive quarter of sequential growth. As reported by Livemint, this growth was driven by new drug-device combination (DDC) capacity, execution of master services agreements (MSAs), alongside 12 launches and growth across all businesses. Net profit increased significantly to ₹93.7 crore from ₹6.37 crore in the same period last year, representing an increase of approximately 1,372% year-on-year. The growth was aided by healthy revenue performance and margin expansion across key metrics.
According to Livemint reports, Onesource reported EBITDA of ₹163.3 crore, marking a 53% year-on-year jump and 32% quarter-on-quarter growth. Operating leverage supported margin expansion, while the addition of new capacity provided a runway for further volume growth. The company's EBITDA margin expanded by over 300 basis points to 31.6% from 28.4% on a year-on-year basis, indicating improved operational efficiency and cost management.
Commenting on the performance, Neeraj Sharma, CEO and Managing Director of OneSource Specialty Pharma Limited, said, "Q2 delivered strong sequential growth, led by new DDC capacity. With our second commercial cartridge line, H2 will see new launches and a significant ramp-up in commercial volumes." As reported by Livemint, Sharma added that biologics momentum remained strong, with yet another US biotech onboarded during the quarter. The company has maintained its FY28 guidance of $400 million in organic revenue and a steady-state EBITDA margin of 40%.
Since its listing in January 2025, the stock has witnessed considerable volatility, with no sustained directional trend. According to Livemint, gains recorded during some periods were subsequently erased in the following months. At around ₹1,598 apiece, the stock remains nearly 29% below its listing-era highs, while trading about 50% above its record low of ₹1,057. The company's DDC capacity is expected to triple by FY28 as two cartridge lines begin commercial operations and factory acceptance testing (FAT) for the third line is completed, with the biologics platform gaining momentum through new customer wins and a robust pipeline of opportunities.
